Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics, Big Data and the Cloud E2. Personalized Medicine – Diagnostics & Therapy Image: http://www.jamesphillips.org/wp-content/uploads/2011/07/Engineered-Neural-Tissue-300x261.jpg
18
Embed
Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Engineered Cells and Tissues
Locksley McGann, PhD
ProfessorDepartment of Laboratory Medicine and Pathology
• Public banking– Mothers donate the umbilical cord blood after birth– The cord blood is recovered, typed and cryopreserved– Cell characteristics are listed on international registries
• Private banking– The mother pays to recover and cryopreserve the cord
blood for future use– Cell characteristics are not typed or listed on registries– There are about 12 private banks in Canada
Adult stem cell examples - 3
• In March, 2011, the provincial and territorial ministries of health (except Quebec) provided funding for the Canadian Blood Services to create a national umbilical cord blood bank
• There will be several collection sites across the country
• There will be 2 processing/storage/distribution sites– one in Ottawa (2013)– the other in Edmonton (2014)
Umbilical cord blood
Tissues
• General process:– Cadaveric donors– Tissues recovered in an operating room– Processed and stored (mostly frozen)– Distributed to hospitals
• Donor tissues commonly transplanted include:– Bone for repair– Corneas to restore vision– Skin for severe burns– Heart valves, blood vessels– Some engineered tissues approaching routine use
• Therapies utilizing living cells and tissues are increasingly begin used in treating patients
• Analytics will play an increasingly important role to:– define specific requirements for each patient– design and develop the appropriate biological modalities– monitor the patient to track the performance of the
grafted cells/tissues, and to improve procedures
• These developments require development of partnerships between the disciplines